CLINICAL_TRIALS
trial_result
· 2024-08-09
Clinical Trial Update: Oral ISL QM as PrEP in Cisgender Women at High Risk for HIV-1 Infection (MK-8591-022) [Phase 3]
Summary
A Phase 3 trial evaluating oral islatravir (MK-8591) for HIV-1 PrEP in cisgender women at high risk was terminated, with results posted in 2024.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Merck Sharp & Dohme LLC | Conditions: HIV-I, Human Immunodeficiency Virus Type 1 | Phase 3 | Status: TERMINATED | Results posted: 2024-08-09